Morgan Stanley (NYSE:MS) analyst David Lebovitz maintained a Buy rating on Blueprint Medicines (NASDAQ:BPMC) on Tuesday, setting a price target of $100, which is approximately 0.87% below the present share price of $100.88.
Lebovitz expects Blueprint Medicines to post earnings per share (EPS) of -$2.28 for the fourth quarter of 2020.
The current consensus among 14 TipRanks analysts is for a Strong Buy rating of shares in Blueprint Medicines, with an average price target of $103.
The analysts price targets range from a high of $121 to a low of $89.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $8.34 million and a net profit of -$125.04 million. The company's market cap is $5.58 billion.
According to TipRanks.com, Morgan Stanley analyst David Lebovitz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.3% and a 62.86% success rate.
Blueprint Medicines Corp . is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.